The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Investors understand that their principal will be at very high risk
Category
Sector Funds
Launch Date
06-Dec-24
Scheme Benchmark
NA
AUM ( in Cr.)
107.51
portfolio price to book value
8.9
investing style?
Large Growth
fund manager?
Anandha Padmanabhan Anjeneyan,Utsav Mehta,Sharma Vivek
inception date (regular plan)
expense ratio (regular plan) %
2.38